Trimodulin for COVID-19: real-time analysis

Download Image

Post

c19early.org

Trimodulin for COVID-19

1 study with 166 patients

Serious outcome risk

Trimodulin

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Trimodulin studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−17%

Mortality (1)−17%

RCTs (1)−17%

Late (1)−17%

00.511.5+

← Trimodulin
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Aug 13 2024	Agafina et al., European Journal of Medical Research, doi:10.1186/s40001-024-02008-x	Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)
Aug 13 2024	17% higher mortality (p=0.7), 2% lower progression (p=1), and 9% longer ventilation (p=0.62). RCT 166 severe COVID-19 patients on non-invasive ventilation or high-flow oxygen showing no significant difference in clinical deterioration or mortality with trimodulin treatment compared to placebo. In a post hoc analysis of a subgroup ..